Chlorthalidone for Hypertension

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Hypertension+2 More
Chlorthalidone - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial found that while thiazide diuretics are not as potent as loop diuretics, they may be associated with less acute kidney injury.

Eligible Conditions
  • Hypertension
  • Chronic Kidney Diseases

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 8 Secondary · Reporting Duration: Baseline to 12 weeks

Baseline to 12 weeks
Change From Baseline at Each 4 Week Visit in Body Volume in the Chlorthalidone Group Compared to Placebo. No Adjustments Will be Made for Multiple Comparisons.
Change From Baseline at Each 4 Week Visit in Log of Aldosterone and Log of Renin in the Chlorthalidone Group Compared to Placebo. No Adjustments Will be Made for Multiple Comparisons.
Change From Baseline at Each 4 Week Visit in Log of N-terminal Pro B-type Natriuretic Peptide (NTproBNP) in the Chlorthalidone Group Compared to Placebo. No Adjustments Will be Made for Multiple Comparisons.
Change From Baseline to 12 Weeks in Systolic Ambulatory Blood Pressure in the Chlorthalidone Group Compared to Placebo.
Change from baseline at each 4 week visit in body volume in the chlorthalidone group compared to placebo. No adjustments will be made for multiple comparisons.
Change from baseline at each 4 week visit in log of N-terminal pro B-type natriuretic peptide (NTproBNP) in the chlorthalidone group compared to placebo. No adjustments will be made for multiple comparisons.
Change from baseline at each 4 week visit in log of aldosterone and log of renin in the chlorthalidone group compared to placebo. No adjustments will be made for multiple comparisons.
Change from baseline to 12 weeks in systolic ambulatory blood pressure in the chlorthalidone group compared to placebo.
Changes in Albuminuria From Baseline at Each 4 Week Visit in the Log Transformed Albumin/Creatinine Ratio in the Chlorthalidone Group Compared to Placebo
Changes in albuminuria from baseline at each 4 week visit in the log transformed albumin/creatinine ratio in the chlorthalidone group compared to placebo

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Side Effects for

All Study Participants
5%Other
3%Headache
2%Fatigue
1%Nausea
1%Dizziness
This histogram enumerates side effects from a completed 2014 Phase 4 trial (NCT01203852) in the All Study Participants ARM group. Side effects include: Other with 5%, Headache with 3%, Fatigue with 2%, Nausea with 1%, Dizziness with 1%.

Trial Design

2 Treatment Groups

Chlorthalidone
1 of 2
Placebo
1 of 2
Experimental Treatment
Non-Treatment Group

160 Total Participants · 2 Treatment Groups

Primary Treatment: Chlorthalidone · Has Placebo Group · Phase 2

Chlorthalidone
Drug
Experimental Group · 1 Intervention: Chlorthalidone · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Chlorthalidone
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to 12 weeks

Who is running the clinical trial?

Indiana UniversityLead Sponsor
868 Previous Clinical Trials
748,758 Total Patients Enrolled
12 Trials studying Hypertension
5,017 Patients Enrolled for Hypertension
Rajiv Agarwal, MDPrincipal InvestigatorIndiana University
5 Previous Clinical Trials
381 Total Patients Enrolled
3 Trials studying Hypertension
248 Patients Enrolled for Hypertension

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 2nd, 2021

Last Reviewed: October 17th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.